Search
Lipocine Inc
LPCNAdd to Watchlist
2.390USD
-0.070-2.85%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.72MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Lipocine Inc is 7.00, ranking 314 out of 387 in the Biotechnology & Medical Research industry. The average price target is 6.88, with a high of 7.00 and a low of 6.75.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+143.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Lipocine Inc
LPCN
2
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lipocine Inc's expected revenue for the next quarter?
Lipocine Inc's expected revenue is 156.50K.
What is Lipocine Inc's price target?
Analysts forecast that Lipocine Inc's price target is USD 6.88, with the highest forecast at USD 7.00 and the lowest forecast at USD 6.75.
How have Lipocine IncLPCN's recent earnings per share performed?
The market expectation was USD -0.54, while Lipocine IncLPCN's earnings per share (EPS) for the previous quarter was USD -0.42. EPS for the next quarter is expected at USD -0.43.
What is the analyst rating for Lipocine Inc?
Based on the ratings of Lipocine Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.